BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32313251)

  • 1. Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook.
    Hechtelt Jonker A; Hivert V; Gabaldo M; Batista L; O'Connor D; Aartsma-Rus A; Day S; Sakushima K; Ardigo D
    Nat Rev Drug Discov; 2020 Aug; 19(8):495-496. PubMed ID: 32313251
    [No Abstract]   [Full Text] [Related]  

  • 2. A Global Approach to Rare Diseases Research and Orphan Products Development: The International Rare Diseases Research Consortium (IRDiRC).
    Cutillo CM; Austin CP; Groft SC
    Adv Exp Med Biol; 2017; 1031():349-369. PubMed ID: 29214582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Food and Drug Administration's Office of Orphan Products Development: incentives, grants, and special designations speed therapies for orphan diseases.
    Haffner ME
    Retina; 2005 Dec; 25(8 Suppl):S89-S90. PubMed ID: 16374359
    [No Abstract]   [Full Text] [Related]  

  • 4. An Orphan Drug Framework (ODF) for Canada.
    Lee DK; Wong B
    J Popul Ther Clin Pharmacol; 2014; 21(1):e42-6. PubMed ID: 24671833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translation of rare disease research into orphan drug development: disease matters.
    Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
    Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical dilemmas about orphan drugs for orphan diseases.
    Gunasekera H
    J Paediatr Child Health; 2014 Aug; 50(8):656. PubMed ID: 25080986
    [No Abstract]   [Full Text] [Related]  

  • 7. Ethical dilemmas about orphan drugs for orphan diseases.
    Isaacs D
    J Paediatr Child Health; 2014 Apr; 50(4):249-50. PubMed ID: 24698059
    [No Abstract]   [Full Text] [Related]  

  • 8. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IRDiRC Drug Repurposing Guidebook: making better use of existing drugs to tackle rare diseases.
    Hechtelt Jonker A; Day S; Gabaldo M; Stone H; de Kort M; O'Connor DJ; Pasmooij AMG
    Nat Rev Drug Discov; 2023 Dec; 22(12):937-938. PubMed ID: 37872324
    [No Abstract]   [Full Text] [Related]  

  • 10. Orphan drugs and orphan tests in the USA.
    Thoene JG
    Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
    [No Abstract]   [Full Text] [Related]  

  • 11. Awareness of orphan therapies offer opportunities for pharmacists.
    Traynor K
    Am J Health Syst Pharm; 2013 Sep; 70(18):1564, 1566. PubMed ID: 23988596
    [No Abstract]   [Full Text] [Related]  

  • 12. [Orphan drugs. Drugs for treatment of rare diseases].
    Hennemann A
    Med Monatsschr Pharm; 2004 Aug; 27(8):256-9. PubMed ID: 15382448
    [No Abstract]   [Full Text] [Related]  

  • 13. Orphan drug development in China: progress and challenges.
    Zhang S; Chen L; Zhang Z; Zhao Y
    Lancet; 2019 Sep; 394(10204):1127-1128. PubMed ID: 31571591
    [No Abstract]   [Full Text] [Related]  

  • 14. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.
    Herder M
    Account Res; 2013; 20(4):227-69. PubMed ID: 23805831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Orphan diseases, rare diseases, time to get mobilised].
    Cordier JF
    Rev Prat; 2006 Jan; 56(2):123-4. PubMed ID: 16584035
    [No Abstract]   [Full Text] [Related]  

  • 16. Is it time to revisit orphan drug policies?
    McCabe C; Stafinski T; Menon D
    BMJ; 2010 Sep; 341():c4777. PubMed ID: 20861098
    [No Abstract]   [Full Text] [Related]  

  • 17. Orphan products: hope for people with rare diseases.
    Rados C
    FDA Consum; 2003; 37(6):10-5. PubMed ID: 14986582
    [No Abstract]   [Full Text] [Related]  

  • 18. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
    Oo C; Rusch LM
    J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
    Stockklausner C; Lampert A; Hoffmann GF; Ries M
    Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orphan Drug Act passes quarter-century milestone in fight against rare diseases.
    Lavine G
    Am J Health Syst Pharm; 2008 Jul; 65(13):1205, 1210. PubMed ID: 18574005
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.